Reproductive Health — MCQs
On this page
A 35-year-old woman with BMI 31 kg/m² presents 96 hours after unprotected sexual intercourse requesting emergency contraception. She has regular 28-day cycles and calculates she is on day 16 of her cycle. She has no other relevant medical history and takes no regular medications. She has not had any other episodes of unprotected intercourse this cycle. What is the most appropriate management?
A 51-year-old woman commenced on transdermal estradiol 50 mcg patches twice weekly with cyclical dydrogesterone 10 mg (days 1-14) 10 months ago for menopausal symptoms. She now reports a 9-day episode of heavy vaginal bleeding that started 3 days after completing the progestogen phase. This is longer and heavier than her usual withdrawal bleeds. What is the most appropriate initial management?
According to current UK guidance, what is the minimum age at which the progesterone-only implant (etonogestrel) can be used without being classified as 'off-license' use?
A 54-year-old woman with a BMI of 33 kg/m² and a history of venous thromboembolism 3 years ago on the combined oral contraceptive pill presents with moderate vasomotor symptoms. She stopped HRT 2 months ago due to concerns about health risks after reading media reports. Her last menstrual period was 18 months ago. She requests non-hormonal management. What is the most appropriate first-line non-hormonal treatment?
A 29-year-old woman who is currently breastfeeding her 8-week-old infant presents requesting contraception. She plans to continue breastfeeding for at least 6 months. She is fully breastfeeding and has not had a menstrual period since delivery. She does not wish to have another pregnancy in the near future. What is the most appropriate contraceptive advice?
A 48-year-old woman presents requesting HRT for troublesome menopausal symptoms. She has a history of a DVT 6 years ago during long-haul flight immobilisation, for which she was treated with anticoagulation for 3 months. Thrombophilia screening at the time was negative. She has had no further thrombotic events. Her BMI is 24 kg/m² and she is a non-smoker with no other medical conditions. What is the most appropriate initial HRT recommendation?
A 38-year-old woman attends for review 4 weeks after copper IUD insertion for emergency contraception. She reports that the IUD was inserted 4 days after unprotected sexual intercourse. She has had no bleeding since insertion and her pregnancy test today is positive. An ultrasound scan confirms an intrauterine pregnancy of 6 weeks gestation. The IUD threads are not visible at the cervical os. She wishes to continue with the pregnancy. What is the most appropriate management?
A 56-year-old woman presents with persistent vulvovaginal atrophy symptoms despite 6 months of regular vaginal estrogen therapy. She has been using estradiol 10 mcg vaginal tablets twice weekly. She had a natural menopause at age 52 and is not on systemic HRT. Examination confirms vaginal atrophy with no concerning features. What is the most appropriate next step in management?
A 32-year-old woman with type 1 diabetes mellitus and proliferative diabetic retinopathy presents requesting contraception. Her HbA1c is 58 mmol/mol (7.5%). She has no other vascular complications and her blood pressure is 125/78 mmHg. She has a BMI of 27 kg/m² and does not smoke. She would prefer a long-acting method. According to UKMEC, what is the contraceptive classification for the levonorgestrel intrauterine system in this patient?
What is the primary reason for recommending that women who have undergone hysterectomy with ovarian conservation should be offered HRT at the time of natural menopause even if asymptomatic?
Reproductive Health UK Medical PG Practice Questions and MCQs
Question 81: A 35-year-old woman with BMI 31 kg/m² presents 96 hours after unprotected sexual intercourse requesting emergency contraception. She has regular 28-day cycles and calculates she is on day 16 of her cycle. She has no other relevant medical history and takes no regular medications. She has not had any other episodes of unprotected intercourse this cycle. What is the most appropriate management?
- A. Prescribe ulipristal acetate 30 mg single dose
- B. Prescribe levonorgestrel 1.5 mg single dose
- C. Prescribe double-dose levonorgestrel 3 mg due to elevated BMI
- D. Arrange copper IUD insertion (Correct Answer)
- E. Advise that emergency contraception is not effective beyond 72 hours
Explanation: ***Arrange copper IUD insertion*** - The **copper IUD** is the most effective method of emergency contraception, offering over **99% efficacy**, and can be inserted up to **120 hours (5 days)** after unprotected sexual intercourse or within **5 days of predicted ovulation**. - It is the gold standard choice regardless of the patient's **BMI** and provides immediate and ongoing contraception, making it ideal for this patient presenting at 96 hours with an elevated BMI. *Prescribe ulipristal acetate 30 mg single dose* - While licensed for use up to **120 hours**, it is less effective than the **copper IUD**, particularly when intercourse occurs near the predicted **ovulation window** (day 16). - Its efficacy is significantly reduced in women with a **BMI >30 kg/m²**, making it a secondary choice compared to the IUD in this clinical scenario. *Prescribe levonorgestrel 1.5 mg single dose* - **Levonorgestrel** is primarily effective within **72 hours** of unprotected intercourse, rendering it largely ineffective at **96 hours** post-exposure. - Its mechanism of action to inhibit or delay ovulation is unlikely to be successful if ovulation has already occurred or is imminent, which is probable on day 16 of a regular cycle. *Prescribe double-dose levonorgestrel 3 mg due to elevated BMI* - Although a **double dose** (3 mg) of levonorgestrel is recommended for women with a **BMI >26 kg/m²** or weight >70 kg, it still must be administered within the **72-hour window** to be effective. - Clinical guidelines prioritize the **copper IUD** as the first-line recommendation for women with an **elevated BMI** due to the significantly reduced efficacy of oral emergency contraceptive pills. *Advise that emergency contraception is not effective beyond 72 hours* - This statement is incorrect as both **ulipristal acetate** and the **copper IUD** are effective and indicated for use up to **120 hours (5 days)** after unprotected intercourse. - Professional guidelines strongly recommend offering the **copper IUD** to all women presenting for emergency contraception beyond 72 hours to maximize the chances of preventing pregnancy.
Question 82: A 51-year-old woman commenced on transdermal estradiol 50 mcg patches twice weekly with cyclical dydrogesterone 10 mg (days 1-14) 10 months ago for menopausal symptoms. She now reports a 9-day episode of heavy vaginal bleeding that started 3 days after completing the progestogen phase. This is longer and heavier than her usual withdrawal bleeds. What is the most appropriate initial management?
- A. Increase the progestogen dose to dydrogesterone 20 mg daily
- B. Reassure that irregular bleeding is normal in the first year of HRT
- C. Arrange urgent transvaginal ultrasound scan (Correct Answer)
- D. Switch to continuous combined HRT preparation
- E. Stop HRT and repeat pelvic examination in 4 weeks
Explanation: ***Arrange urgent transvaginal ultrasound scan*** - The patient is on **sequential HRT** and experiences **heavy, prolonged, irregular bleeding** 10 months into treatment, which is beyond the expected initial adaptation phase. - This requires urgent investigation to rule out **endometrial pathology**, such as **hyperplasia** or **carcinoma**, making a **transvaginal ultrasound** the appropriate initial diagnostic step to assess **endometrial thickness**. *Increase the progestogen dose to dydrogesterone 20 mg daily* - While increased progestogen might be considered for **insufficient endometrial protection**, it should only be done *after* excluding any underlying **pathology** through investigation. - Modifying the HRT regimen without proper investigation would dangerously delay the diagnosis of potential **endometrial cancer** or other significant issues. *Reassure that irregular bleeding is normal in the first year of HRT* - Although unscheduled bleeding is common in the first **3 to 6 months** of HRT, this patient is 10 months into treatment and her bleeding is **heavier and longer** than her usual withdrawal pattern. - This significant change in bleeding pattern after the initial stabilization period is a **red flag** and requires immediate investigation, not reassurance. *Switch to continuous combined HRT preparation* - **Continuous combined HRT** is generally reserved for women who are at least one year post-menopause or after successful sequential HRT, to avoid erratic bleeding. - Switching regimens at this point would obscure the clinical picture and fail to address the critical need for **endometrial assessment** of the current abnormal bleeding. *Stop HRT and repeat pelvic examination in 4 weeks* - Stopping HRT would not resolve the need to investigate a suspicious bleeding event that has already occurred and is abnormal for her HRT duration. - Delaying assessment by 4 weeks is inappropriate, as guidelines recommend **urgent evaluation** for abnormal uterine bleeding in women on HRT, particularly after the initial few months.
Question 83: According to current UK guidance, what is the minimum age at which the progesterone-only implant (etonogestrel) can be used without being classified as 'off-license' use?
- A. 12 years
- B. 16 years
- C. There is no minimum age restriction
- D. 13 years
- E. 18 years (Correct Answer)
Explanation: ***18 years*** - According to the **Summary of Product Characteristics (SmPC)**, the etonogestrel implant (Nexplanon) is officially licensed for use in women aged **18 to 40 years** in the UK. - While it is frequently and safely used in clinical practice for younger adolescents, its use below the age of **18 years** is technically classified as **off-license** use. *12 years* - There is no clinical or regulatory guideline that specifies **12 years** as the minimum age for licensed use of the implant. - Although a child of this age could potentially receive it under **Fraser guidelines** if deemed competent, it would still be considered **off-license** in terms of product licensing. *16 years* - While **16 years** is often associated with the age of medical consent (competence), it does not align with the manufacturer's **licensing requirements** for this specific device. - Clinical data supporting the implant's efficacy and safety in the **under-18 population** was not primary to the original license application, leading to its current status. *There is no minimum age restriction* - While professional bodies like the **Faculty of Sexual and Reproductive Healthcare (FSRH)** state there are no medical prohibitions for use in younger girls, the **legal licensing status** of the product does have a specific age threshold. - Prescribing the implant to any person under **18 years** requires the clinician to acknowledge and document the **off-license** nature of the prescription. *13 years* - **13 years** is a significant age regarding safeguarding and **sexual activity reporting** protocols, but it is not the age specified for the medication's license. - Like other pediatric ages, use in a 13-year-old is supported by **clinical best practices** but remains outside the manufacturer's **official license**.
Question 84: A 54-year-old woman with a BMI of 33 kg/m² and a history of venous thromboembolism 3 years ago on the combined oral contraceptive pill presents with moderate vasomotor symptoms. She stopped HRT 2 months ago due to concerns about health risks after reading media reports. Her last menstrual period was 18 months ago. She requests non-hormonal management. What is the most appropriate first-line non-hormonal treatment?
- A. Cognitive behavioural therapy (Correct Answer)
- B. Paroxetine 20 mg daily
- C. Venlafaxine 75 mg daily
- D. Clonidine 50 mcg twice daily
- E. Black cohosh supplement
Explanation: ***Cognitive behavioural therapy***- **NICE guidelines** recommend CBT as the first-line non-hormonal intervention for **vasomotor symptoms** and low mood associated with menopause.- It is highly appropriate for this patient who has a contraindication to HRT (**history of VTE**) and specifically requests a non-hormonal approach without pharmacological side effects.*Paroxetine 20 mg daily*- **SSRIs** like paroxetine are considered second-line options and are generally reserved if non-pharmacological methods like **CBT** are ineffective or declined.- They are associated with side effects such as **nausea**, insomnia, and **sexual dysfunction**, making them less desirable as an initial step.*Venlafaxine 75 mg daily*- This **SNRI** can reduce the severity of hot flushes but is not the first-line non-hormonal recommendation according to current clinical standards.- It carries a risk of side effects including **increased blood pressure** and significant **withdrawal symptoms** upon discontinuation.*Clonidine 50 mcg twice daily*- A centrally acting **alpha-2 agonist** that has limited efficacy in treating vasomotor symptoms compared to other available options.- Frequent side effects such as **dry mouth**, **drowsiness**, and hypotension often lead to poor patient compliance.*Black cohosh supplement*- **Herbal preparations** like black cohosh lack robust clinical evidence for efficacy and are not regulated with the same stringency as pharmaceuticals.- There are significant safety concerns regarding potential **hepatotoxicity** (liver damage) associated with its use.
Question 85: A 29-year-old woman who is currently breastfeeding her 8-week-old infant presents requesting contraception. She plans to continue breastfeeding for at least 6 months. She is fully breastfeeding and has not had a menstrual period since delivery. She does not wish to have another pregnancy in the near future. What is the most appropriate contraceptive advice?
- A. Combined oral contraceptive pill can be safely started immediately
- B. Lactational amenorrhoea method (LAM) provides adequate protection until 6 months postpartum
- C. Progesterone-only pill should be started and can be commenced immediately (Correct Answer)
- D. Copper IUD insertion should be delayed until 6 months postpartum
- E. No contraception is needed until menstruation returns
Explanation: ***Progesterone-only pill should be started and can be commenced immediately***- The **progesterone-only pill (POP)** is highly suitable for breastfeeding women as it does not interfere with **milk production** or infant development.- It is categorized as **UKMEC 1** (no restrictions) and can be safely initiated at any time following delivery to provide reliable protection.*Combined oral contraceptive pill can be safely started immediately*- **Combined oral contraceptives (COCP)** are generally avoided in breastfeeding women before 6 weeks postpartum due to an increased risk of **venous thromboembolism** and potential reduction in **milk supply**.- It is classified as **UKMEC 4** (unacceptable health risk) before 6 weeks and **UKMEC 3** between 6 weeks and 6 months for breastfeeding mothers.*Lactational amenorrhoea method (LAM) provides adequate protection until 6 months postpartum*- While **LAM** is 98% effective, it requires strict adherence to three criteria: **exclusive breastfeeding**, remaining **amenorrhoeic**, and the infant being **under 6 months** old.- Because this patient explicitly desires to avoid pregnancy in the near future, relying solely on LAM may be riskier than using a **hormonal or barrier method** as a backup.*Copper IUD insertion should be delayed until 6 months postpartum*- A **Copper IUD** does not need to be delayed; it can be safely inserted starting from **4 weeks postpartum** (**UKMEC 1**).- It is an excellent **long-acting reversible contraceptive (LARC)** option that is hormone-free and does not affect breastfeeding.*No contraception is needed until menstruation returns*- This is a common misconception; **ovulation** can occur before the first postpartum menstrual period, leading to a risk of **unplanned pregnancy**.- Relying on the return of menses is unreliable compared to established methods like the **POP** or **LAM** criteria.
Question 86: A 48-year-old woman presents requesting HRT for troublesome menopausal symptoms. She has a history of a DVT 6 years ago during long-haul flight immobilisation, for which she was treated with anticoagulation for 3 months. Thrombophilia screening at the time was negative. She has had no further thrombotic events. Her BMI is 24 kg/m² and she is a non-smoker with no other medical conditions. What is the most appropriate initial HRT recommendation?
- A. Standard oral continuous combined HRT
- B. Transdermal estrogen with micronised progesterone (Correct Answer)
- C. HRT is contraindicated due to VTE history
- D. Tibolone
- E. Selective serotonin reuptake inhibitor instead of HRT
Explanation: ***Transdermal estrogen with micronised progesterone*** - **Transdermal estrogen** is preferred in patients with a history of **venous thromboembolism (VTE)** as it avoids **first-pass hepatic metabolism** and does not increase the synthesis of clotting factors. - **Micronised progesterone** (Utrogestan) is used as the progestogenic component because it is considered **metabolically neutral** and carries a lower risk of VTE and breast cancer compared to synthetic progestogens. *Standard oral continuous combined HRT* - **Oral estrogen** significantly increases the risk of **VTE** by increasing levels of prothrombin and decreasing levels of antithrombin; this is avoided in patients with a history of DVT. - Although her DVT was **provoked** and occurred over 5 years ago, oral therapy remains a **UKMEC 3** risk (risks generally outweigh benefits), making it a poor initial choice. *HRT is contraindicated due to VTE history* - HRT is not **absolutely contraindicated** if the VTE was **provoked** (e.g., long-haul flight), the event was more than 5 years ago, and **thrombophilia screening** was negative. - Management involves a balanced discussion of risks, and the **transdermal route** provides a safe enough profile to manage severe menopausal symptoms in this patient group. *Tibolone* - **Tibolone** is a synthetic compound with estrogenic, progestogenic, and androgenic properties that still carries a **VTE risk** similar to that of oral HRT. - It is generally reserved for postmenopausal women who prefer a single-pill option but is not recommended for those specifically requiring an **ultra-low VTE risk** profile. *Selective serotonin reuptake inhibitor instead of HRT* - **SSRIs** are non-hormonal alternatives used to treat **vasomotor symptoms** but are significantly **less effective** than HRT for symptom control. - These should be considered second-line therapy for women who have a **contraindication** to HRT or those who actively choose to avoid hormone therapy.
Question 87: A 38-year-old woman attends for review 4 weeks after copper IUD insertion for emergency contraception. She reports that the IUD was inserted 4 days after unprotected sexual intercourse. She has had no bleeding since insertion and her pregnancy test today is positive. An ultrasound scan confirms an intrauterine pregnancy of 6 weeks gestation. The IUD threads are not visible at the cervical os. She wishes to continue with the pregnancy. What is the most appropriate management?
- A. Prescribe prophylactic antibiotics and remove IUD at 12 weeks gestation
- B. Attempt IUD removal under ultrasound guidance immediately
- C. Arrange urgent hysteroscopy for IUD removal
- D. Leave the IUD in situ and arrange close antenatal surveillance (Correct Answer)
- E. Advise termination of pregnancy due to high risk of complications
Explanation: ***Leave the IUD in situ and arrange close antenatal surveillance*** - When **IUD threads are not visible** at the cervical os in a desired pregnancy, attempting removal by instrumentation within the uterine cavity significantly increases the risk of **miscarriage** or infection. - The most appropriate management is to leave the IUD in place and provide **close antenatal surveillance**, counseling the patient about the elevated risks of **preterm birth** and **second-trimester miscarriage**. *Prescribe prophylactic antibiotics and remove IUD at 12 weeks gestation* - There is no evidence to support the routine use of **prophylactic antibiotics** when an IUD is retained in a pregnancy without signs of infection. - Delaying removal to **12 weeks gestation** does not mitigate the risks associated with non-visible threads and instrumental removal, which should generally be avoided if threads are not easily accessible. *Attempt IUD removal under ultrasound guidance immediately* - Attempting to remove an IUD with **non-visible threads** by instrumentation under ultrasound guidance carries a substantial risk of disrupting the **gestational sac** or causing uterine trauma. - Guidelines advise against intrauterine exploration to retrieve an IUD when the strings are not visible, as this poses a higher risk of **miscarriage** than leaving it in situ. *Arrange urgent hysteroscopy for IUD removal* - **Hysteroscopy** is absolutely **contraindicated** in a desired ongoing pregnancy due to the high risk of **iatrogenic miscarriage** and potential harm to the fetus. - The procedure involves uterine distension and direct visualization, which is incompatible with the viability of an **early intrauterine pregnancy**. *Advise termination of pregnancy due to high risk of complications* - While a retained IUD increases the risks of **miscarriage** and **preterm delivery**, it is not an absolute medical indication for **termination of pregnancy**, especially when the patient wishes to continue. - Management should respect the patient's autonomy and desire to continue the pregnancy, focusing on **risk counseling** and vigilant monitoring rather than mandatory termination.
Question 88: A 56-year-old woman presents with persistent vulvovaginal atrophy symptoms despite 6 months of regular vaginal estrogen therapy. She has been using estradiol 10 mcg vaginal tablets twice weekly. She had a natural menopause at age 52 and is not on systemic HRT. Examination confirms vaginal atrophy with no concerning features. What is the most appropriate next step in management?
- A. Discontinue vaginal estrogen and prescribe vaginal moisturisers only
- B. Refer to gynaecology for further assessment
- C. Switch to estriol 0.5 mg vaginal cream
- D. Increase frequency of estradiol vaginal tablets to daily use (Correct Answer)
- E. Add systemic HRT with continuous combined preparation
Explanation: ***Increase frequency of estradiol vaginal tablets to daily use*** - When standard twice-weekly dosing of **low-dose vaginal estrogen** fails to control symptoms, increasing to **daily administration** is an appropriate and safe next step in management. - Optimization of the current **topical estrogen** regimen is required before switching medications or considering more invasive specialist referrals. *Discontinue vaginal estrogen and prescribe vaginal moisturisers only* - **Vaginal moisturizers** are non-hormonal lubricants that treat dryness but do not address the underlying physiological **hypoestrogenic changes** of atrophy. - Discontinuing the primary curative treatment for a symptomatic patient with **confirmed atrophy** would result in a worsening of symptoms. *Refer to gynaecology for further assessment* - Referral is not indicated at this stage because **conservative optimization** of treatment in primary care has not yet been exhausted. - Specialist assessment is typically reserved for cases where there are **concerning features** (e.g., bleeding, masses) or if symptoms remain refractory after maximum topical therapy. *Switch to estriol 0.5 mg vaginal cream* - Switching between different low-dose estrogen formulations (tablets to creams) is unlikely to be more effective than **increasing the dose/frequency** of the current medication. - **Vaginal creams** are equivalent in efficacy to tablets; the issue here is the **dosing frequency** rather than the delivery vehicle. *Add systemic HRT with continuous combined preparation* - **Systemic HRT** is not the first-line treatment for isolated **genitourinary syndrome of menopause (GSM)** when vasomotor symptoms are absent. - Systemic therapy carries a higher **side-effect profile** and risks compared to targeted, low-dose **topical estrogen therapy**.
Question 89: A 32-year-old woman with type 1 diabetes mellitus and proliferative diabetic retinopathy presents requesting contraception. Her HbA1c is 58 mmol/mol (7.5%). She has no other vascular complications and her blood pressure is 125/78 mmHg. She has a BMI of 27 kg/m² and does not smoke. She would prefer a long-acting method. According to UKMEC, what is the contraceptive classification for the levonorgestrel intrauterine system in this patient?
- A. UKMEC 1 - no restriction on use
- B. UKMEC 2 - advantages generally outweigh risks (Correct Answer)
- C. UKMEC 3 - risks generally outweigh advantages
- D. UKMEC 4 - unacceptable health risk
- E. UKMEC classification depends on duration of diabetes
Explanation: ***UKMEC 2 - advantages generally outweigh risks***- The **levonorgestrel intrauterine system (LNG-IUS)** is generally classified as **UKMEC 1** for women with diabetes without vascular complications.- However, the presence of **proliferative diabetic retinopathy**, a **microvascular complication**, elevates the classification to **UKMEC 2**. This means the benefits of effective contraception still generally outweigh the theoretical or proven risks, but careful consideration is required.*UKMEC 1 - no restriction on use*- This classification applies to women with **diabetes mellitus** who have **no evidence of vascular disease** (e.g., nephropathy, retinopathy, neuropathy).- The patient's **proliferative diabetic retinopathy** signifies established microvascular damage, thus precluding a UKMEC 1 classification for the LNG-IUS.*UKMEC 3 - risks generally outweigh advantages*- **UKMEC 3** for contraception in diabetic patients is typically reserved for methods with higher systemic hormonal impact, such as **combined hormonal contraceptives (CHCs)**, especially in the presence of vascular disease or diabetes duration >20 years.- The **LNG-IUS** delivers progestogen locally with minimal systemic absorption, making its impact on metabolic parameters and cardiovascular risk negligible compared to CHCs, thus it is not typically a UKMEC 3 for diabetes complications.*UKMEC 4 - unacceptable health risk*- A **UKMEC 4** classification indicates an unacceptable health risk and the method should not be used.- For the **LNG-IUS**, **diabetes mellitus**, even with **vascular complications** like retinopathy, does not constitute a **UKMEC 4** contraindication. Such classifications are usually for conditions like active pelvic inflammatory disease or certain uterine pathologies.*UKMEC classification depends on duration of diabetes*- While **duration of diabetes** (>20 years) can influence the UKMEC classification, particularly for **combined hormonal contraceptives**, it is not the primary determinant for the **LNG-IUS** in this patient.- The presence of **vascular complications** (like **proliferative retinopathy**) is the key factor that elevates the **LNG-IUS** classification from UKMEC 1 to UKMEC 2, regardless of diabetes duration.
Question 90: What is the primary reason for recommending that women who have undergone hysterectomy with ovarian conservation should be offered HRT at the time of natural menopause even if asymptomatic?
- A. To prevent surgical menopause syndrome
- B. To reduce the risk of premature ovarian insufficiency
- C. To maintain bone density and reduce cardiovascular risk (Correct Answer)
- D. To prevent postoperative adhesion formation
- E. To reduce the risk of ovarian cancer
Explanation: ***To maintain bone density and reduce cardiovascular risk***- Women undergoing **natural menopause**, even with **ovarian conservation**, experience a decline in **estrogen**, which leads to an increased risk of **osteoporosis** and **cardiovascular disease**.- **Estrogen-only HRT** (feasible in women without a uterus) helps to mitigate these risks by supporting **bone mineral density** and improving **cardiovascular health**.*To prevent surgical menopause syndrome*- **Surgical menopause** is an acute, severe onset of menopausal symptoms caused by the abrupt loss of ovarian function after **bilateral oophorectomy**.- In women with **ovarian conservation**, menopause occurs naturally and gradually, leading to a typically milder and slower onset of symptoms, thus not fitting the definition of surgical menopause syndrome.*To reduce the risk of premature ovarian insufficiency*- **Hysterectomy** might slightly advance the age of natural menopause, but it does not directly cause **premature ovarian insufficiency (POI)**, which is the cessation of ovarian function before age 40.- HRT is a treatment for the symptoms and long-term consequences of POI, not a preventive measure against its occurrence.*To prevent postoperative adhesion formation*- **Postoperative adhesions** are fibrous bands that form between organs after surgery, caused by tissue injury and healing processes.- **Hormone replacement therapy** has no known mechanism or clinical evidence to prevent or reduce the formation of **postoperative adhesions**.*To reduce the risk of ovarian cancer*- **Ovarian conservation** means the ovaries are still present and functioning, maintaining the pre-existing risk of **ovarian cancer**.- HRT, particularly **estrogen-progestogen therapy**, may in fact slightly increase the risk of ovarian cancer, and it is not recommended for cancer prevention.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free